GC Pharma said Monday it received an "AA" rating in the latest environmental, social and governance assessment released by Morgan Stanley Capital International, or MSCI.
MSCI has evaluated key ESG issues for about 8,500 listed companies worldwide each year since 1999, assigning ratings on a seven-step scale from AAA to CCC.
In this year’s review, GC Pharma was rated above industry peers in environmental impact management, corporate ethics, and product quality and safety management, lifting its score by one notch from the previous assessment. The company’s rating has risen for three consecutive years, from B in 2023 to A in 2024 and AA this year.
The company said the upgrade reflected steps including building an environmental risk management system and cutting air pollutant emissions, strengthening anti-corruption training for employees, establishing a response system to stabilize pharmaceutical supplies, and adopting a responsible marketing policy.
Kim Seong-yeol, head of GC Pharma’s management administration office, said the AA rating "shows our ESG capabilities have been recognized externally," adding that the company will "continue building a sustainable management system that meets global standards."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.